Back to search results

Gait Analysis in Parkinson's Disease and Related Disorders

This observational study is looking at how walking patterns, or "gait signatures," differ in people with Parkinson's disease and similar conditions compared to healthy individuals. Researchers want to see if these differences can be measured and predicted. You might be eligible if you are between 18 and 85 years old and have certain symptoms like slow movement (bradykinesia), tremor, stiffness (rigidity), or balance problems. Some participants with neurological disease may have an optional second visit where they temporarily stop their anti-Parkinson medication or Deep Brain Stimulation to see how it affects their walking. The main goal is to measure gait speed over about one year. The study's current status is unclear.

Study design
This is an observational study planning to enroll 120 participants, including those with Parkinson's disease, other Parkinsonian disorders, and healthy controls.
What's involved
You would walk on a special walkway with pressure sensors for 9 trials at different speeds. Some participants may have an optional second visit involving temporarily stopping medication or Deep Brain Stimulation and walking an additional 9 trials.
Compensation
Not stated in the trial record.
Follow-up
Gait speed will be measured throughout the study, which averages one year. Some participants with Parkinson's disease and older healthy controls may be followed for the course of their disease.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02994719

Gait Analysis in Neurological Disease

Active, Not Recruiting
Not specifiedAges 18–85Observational
Beth Israel Deaconess Medical Center
~120 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:Anti-Parkinson medicationDeep Brain Stimulation

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Gait speed
Measured over through study completion, an average of 1 year, with option of PD and older healthy controls to be followed longitudinally for the course of the disease

Conditions

Parkinson's Disease
Parkinsonian Disorders
Atypical Parkinson Disease
Progressive Supranuclear Palsy
Multiple System Atrophy
Corticobasal Degeneration
Gait, Frontal
Huntington Disease
Ataxia, Spinocerebellar

Explore related trials

Corticobasal DegenerationHuntington's DiseaseMultiple System AtrophyNormal pressure hydrocephalusParkinson DiseaseProgressive Supranuclear PalsyVascular Parkinsonism

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-85 (for both healthy and affected subjects).
Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).
Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).
These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).
Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).
Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).

Exclusion

Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).
Currently being treated for major medical illness requiring recent hospitalization (\<14 days) (for both healthy and affected subjects).
Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).
Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).
Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \< 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).

What this trial measures

  • Gait speedthrough study completion, an average of 1 year, with option of PD and older healthy controls to be followed longitudinally for the course of the disease

    Method of assessment: physiological parameter